OKYO Pharma Limited ADR OKYO 深 沪
等待开盘 07-18 09:30:00 美东时间
2.90
-0.060
-2.03%
华盛通- 最 高2.95
- 今 开2.88
- 成交量 28.80万股
- 最 低 2.65
- 昨 收 2.96
- 总市值 1.09亿
- 52周最高 3.11
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.8075
- 委 比 -66.67%
- 总股本 3742.43万
- 历史最高 7.00
- 量 比 1.00
- 振 幅 10.14%
- 历史最低 0.8075
- 每 手 1
- 风险率 0.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
OKYO Pharma Limited received $1.9 million in non-dilutive funding to accelerate the development of urcosimod, its lead drug candidate for treating neuropathic corneal pain (NCP), a debilitating condition with no FDA-approved therapy. The funding supports clinical milestones, R&D expansion, and regulatory progress, enabling the company to pursue its mission without diluting shareholder value. Urcosimod, a lipid-conjugated chemerin peptide agonist,...
07-17 13:00
OKYO Pharma Announces Top-Line Data From Recently Closed 18-Patient Phase 2 Trial Of Urcosimod To Treat NCP
After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly
07-16 21:22
OKYO Pharma to Present at the Bio International Convention
OKYO Pharma announced that its CEO, Dr. Gary S. Jacob, will present at the 2025 Bio International Convention in Boston about urcosimod, a drug candidate for treating neuropathic corneal pain (NCP). NCP causes severe eye discomfort due to nerve damage and inflammation, affecting tens of thousands globally. Urcosimod, a long-acting drug targeting eye inflammation and pain, showed significant results in Phase 2 trials for dry eye disease and is now ...
06-11 12:30
OKYO Pharma CEO to Present at Boston Drug Discovery Summit
OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an update. On May 19, ...
05-19 19:27
OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment
OKYO Pharma (NASDAQ:OKYO) said on Monday that urcosimod, its neuropathic corneal pain treatment, has shown to be stable for over two and a half years in single-use ampoules used for administration to ...
03-31 22:01
美股大行评级 | 潜在涨幅49%！PayPal获机构上调目标价至117美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1096044530357866496.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Dakota Gold(DC)"跑赢大市"评级，目标价从6美元升至7.5美元</p> <p>• 杰富瑞：维持Compass Therapeutics(CMPX)"买入"评级，目标价从7美元升至8美元</p
02-11 18:08
OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence
OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) just unveiled an announcement. On...
01-31 20:29
OKYO Pharma CEO buys 10K shares in firm
OKYO Pharma (NASDAQ:OKYO) said its CEO, Gary Jacob, has bought 10K shares of the firm at $1.04 apiece. The firm added Panetta Partners, an entity in which the executive chair, Gabriele Cerrone, has a ...
01-31 20:04
OKYO Pharma Advances Clinical Trials with Encouraging Interim Results
An update from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. ...
01-30 05:56
OKYO Pharma receives $1.4 million in non-dilutive funding, stock up
OKYO Pharma (NASDAQ:OKYO) Wednesday said that it has received $1.4 million in non-dilutive funding, sending shares up in early trade. The funding will be strategically allocated to support ongoing res...
01-22 20:39
